Lars R. Fransecky
Kiel, SH, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 47 publications
Venetoclax combined with high-dose cytarabine and mitoxantrone for relapsed or refractory acute myeloid leukemia: outcomes and risk stratification.
Journal: Haematologica
Published: April 20, 2026
Treatment sequence with gilteritinib and allogeneic haematopoietic stem cell transplantation in relapsed/refractory FMS-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukaemia patients: A multicentre real-world study.
Journal: British journal of haematology
Published: March 04, 2026
Nationwide analysis of acute promyelocytic leukemia: incidence and patient outcomes in Germany.
Journal: Haematologica
Published: December 23, 2025
Venetoclax and Blinatumomab for adult patients with relapsed/refractory or MRD positive Ph-negative B-cell precursor ALL: phase I part of the GMALL-BLIVEN trial.
Journal: Annals of hematology
Published: November 14, 2025
Isocitrate dehydrogenase 1 mutations drive downregulation of IL1R1 and dysregulated inflammatory response in acute myeloid leukemia.
Journal: Blood cancer journal
Published: September 19, 2025
Epidemiology and survival of patients with T-cell prolymphocytic leukemia.
Journal: Blood cancer journal
Published: September 07, 2025
Venetoclax plus high-dose cytarabine and mitoxantrone as salvage treatment for relapsed or refractory acute myeloid leukaemia (RELAX): a multicentre, single-arm, phase 1/2 trial.
Journal: The Lancet. Haematology
Published: September 01, 2025
Randomized Comparison of Cardiotoxicity With 60 Versus 90 mg Daunorubicin in AML Induction Therapy.
Journal: American journal of hematology
Published: August 18, 2025
Differential prognostic impact of myelodysplasia-related gene mutations in a European cohort of 4978 intensively treated AML patients.
Journal: Leukemia
Published: August 15, 2025
Last Updated: 09/26/2026